{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:01:13Z","timestamp":1790611273128,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,29]]},"DOI":"10.7759\/cureus.95681","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:19:36Z","timestamp":1761754776000},"source":"Crossref","is-referenced-by-count":2,"title":["When Falls Reveal Acidosis: Unmasking Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor\u2013Induced Euglycemic Diabetic Ketoacidosis"],"prefix":"10.7759","author":[{"given":"Japleen","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashima","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Haymov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters AL","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015, 38:1687-93. 10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2015). Accessed. July 16, 2025: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibit...."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor SI","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015, 100:2849-52. 10.1210\/jc.2015-1884","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg RM","year":"2016","unstructured":"Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, Yale JF. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016, 38:2654-2664.e1. 10.1016\/j.clinthera.2016.11.002","journal-title":"Clin Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman Y","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016, 22:753-62. 10.4158\/EP161292.PS","journal-title":"Endocr Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-020-01307-x","article-title":"Euglycemic ketoacidosis","volume":"20","author":"Bonora BM","year":"2020","unstructured":"Bonora BM, Avogaro A, Fadini GP. Euglycemic ketoacidosis. Curr Diab Rep. 2020, 20:25. 10.1007\/s11892-020-01307-x","journal-title":"Curr Diab Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015, 38:1638-42. 10.2337\/dc15-1380","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick M","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017, 376:2300-2. 10.1056\/NEJMc1701990","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa W","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016, 7:135-8. 10.1111\/jdi.12401","journal-title":"J Diabetes Investig"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.03.028","article-title":"Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review","volume":"123","author":"Thiruvenkatarajan V","year":"2019","unstructured":"Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019, 123:27-36. 10.1016\/j.bja.2019.03.028","journal-title":"Br J Anaesth"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v14.i8.1314","article-title":"Sodium-glucose cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: a meta summary of case reports","volume":"14","author":"Juneja D","year":"2023","unstructured":"Juneja D, Nasa P, Jain R, Singh O. Sodium-glucose cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: a meta summary of case reports. World J Diabetes. 2023, 14:1314-22. 10.4239\/wjd.v14.i8.1314","journal-title":"World J Diabetes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6572","article-title":"Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus 3\u2009days after initiating sodium-glucose cotransporter 2 inhibitor while on an extremely low carbohydrate diet: a case report","volume":"10","author":"Inoue A","year":"2022","unstructured":"Inoue A, Katayama A, Sue M, et al.. Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus 3\u2009days after initiating sodium-glucose cotransporter 2 inhibitor while on an extremely low carbohydrate diet: a case report. Clin Case Rep. 2022, 10:e6572. 10.1002\/ccr3.6572","journal-title":"Clin Case Rep"},{"key":"ref14","article-title":"Euglycemic Diabetic Ketoacidosis","author":"Plewa MC","year":"2025","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis. StatPearls Publishing, Treasure Island (FL); 2025."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/396082-when-falls-reveal-acidosis-unmasking-sodium-glucose-co-transporter-2-sglt2-inhibitor-induced-euglycemic-diabetic-ketoacidosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:19:41Z","timestamp":1761754781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/396082-when-falls-reveal-acidosis-unmasking-sodium-glucose-co-transporter-2-sglt2-inhibitor-induced-euglycemic-diabetic-ketoacidosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.95681","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}